AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience
NCT04341103 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2020-04-10
Summary
The utilization of AlloSure to help guide immunosuppression management in solid organ transplant recipients diagnosed with COVID-19
Conditions
- Solid Organ Transplant Rejection
- COVID-19
Sponsors & Collaborators
-
CareDx
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-04-01
- Primary Completion
- 2020-12-01
- Completion
- 2021-03-01
More Related Trials
-
Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
NCT06336863 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
NCT05060991 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Cohort Study of Operationally Tolerant Allograft Recipients
NCT02743793 ·Status: TERMINATED
-
Iguratimod in Kidney Transplant Recipients
NCT02839941 ·Status: UNKNOWN ·Phase: NA
-
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents
NCT01678937 ·Status: COMPLETED
-
Impact of the Microbiota on the Likelihood of Renal Graft Rejection
NCT04736381 ·Status: RECRUITING
-
COVID-19 Protection After Transplant Pilot Study
NCT04969263 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients
NCT06584773 ·Status: RECRUITING ·Phase: PHASE4
-
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
NCT01154387 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients
NCT00419926 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen
NCT00286871 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients
NCT04414735 ·Status: RECRUITING ·Phase: NA
-
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
NCT01424345 ·Status: TERMINATED ·Phase: PHASE4
-
Aerosol Cyclosporine for Prevention of Lung Rejection
NCT00268515 ·Status: COMPLETED ·Phase: PHASE2
-
HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)
NCT05459181 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
NCT03994783 ·Status: TERMINATED ·Phase: PHASE3
-
Renal Transplantation With Immune Monitoring
NCT00419575 ·Status: COMPLETED
-
Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
NCT04104438 ·Status: COMPLETED ·Phase: PHASE4
-
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
NCT00000936 ·Status: TERMINATED ·Phase: PHASE3
-
Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients
NCT04701528 ·Status: COMPLETED ·Phase: PHASE2
-
MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients
NCT06044493 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
NCT06990711 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
NCT00099736 ·Status: COMPLETED ·Phase: PHASE3
-
Immuno-humoral Rejection Markers in Pulmonary Transplant
NCT01791166 ·Status: COMPLETED ·Phase: NA
-
Study of the Link Between Complement Activation and IgA Nephropathy Severity
NCT05234463 ·Status: RECRUITING